How did CHRS manage to reduce operating expenses significantly in Q4 2024?

Coherus BioSciences Inc. (CHRS) did not report any significant reduction in operating expenses in its latest report period, Q4 2024. In fact, the company's financial results for Q4 2024 showed a net loss of $50.7 million, which includes the costs associated with its strategic divestitures and workforce reduction. The company's focus has been on divesting non-core assets, such as UDENYCA, and reducing its workforce to streamline operations and conserve cash. The divestiture of UDENYCA is expected to result in approximately $250 million in cash, providing the company with a financial runway of over two years. Therefore, while the company has not reported a significant reduction in operating expenses, it has taken strategic steps to consolidate its operations and reduce costs through divestitures and workforce reduction.